Hareth Nahi

Antibody Response to Covid-19 mRNA Vaccine (Comirnaty), in Myeloma Patients Treated with High-dose Melphalan and/or… pubmed.ncbi.nlm.nih.gov/34524709/

AddThis | Home authors.elsevier.com/c/1dYxYV-4XDRE…

@VincentRK @IMFmyeloma @MayoCancerCare @MayoClinic Congrats

Dr. Shaji Kumar receiving the Brian G. M. Durie Award for Outstanding Achievement in Myeloma Research at the 12th Annual International Myeloma Working Group (IMWG) summit. Congrats Shaji! Thanks for huge contributions to the field. @IMFmyeloma @MayoCancerCare @MayoClinic

Nya rön ger hopp för behandling av multipelt myelom nyheter.ki.se/nya-ron-ger-ho…

Postdoctoral researcher in cancer biology ki.varbi.com/en/what:job/jo…

@VincentRK @myelomaMD @ADispenzieri @vsanchorawala @NoopurRajeMD @MorieGertz @MyelomaDrKapoor @Taxkourel @MayoMyeloma pubmed.ncbi.nlm.nih.gov/31896106/

@VincentRK @myelomaMD @ADispenzieri @vsanchorawala @NoopurRajeMD @MorieGertz @MyelomaDrKapoor @Taxkourel @MayoMyeloma Give BCL2 inhibitor, the patient has 60-70% chance of harbouring t(11;14) and if so, about 80% chance of responding

Question for hem/onc docs: Newly Diagnosed AL Amyloidosis not in VGPR following frontline ASCT (No induction was given before ASCT). What’s your regimen of choice? @myelomaMD @ADispenzieri @vsanchorawala @NoopurRajeMD @MorieGertz @MyelomaDrKapoor @Taxkourel @MayoMyeloma

Outcome of COVID-19 in multiple myeloma patients in relation to treatment pubmed.ncbi.nlm.nih.gov/32745304/

#EHA - Interesting e-Poster Presentation: (EP1038) CORTICOSTERIOD TAPERING IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA RECEIVING SUBCUTANEOUS DARATUMUMAB (DARA SC): PART 3 OF THE OPEN-LABEL, MULTICENTER, PHASE 1B PAVO STUDY

#EHA - Interesting e-Poster Presentation: (EP914) AUTOLOGOUS NK CELL-BASED IMMUNOTHERAPY FOR MAINTENANCE TREATMENT OF MULTIPLE MYELOMA

Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results … pubmed.ncbi.nlm.nih.gov/32470437/